Clinical Trial Is Favorable for a Prenatal Gene Test
By Andrew Pollack,
The New York Times
| 08. 08. 2012
A new method of prenatal testing that can detect more genetic problems in a fetus than ever before could be headed toward wider use after encouraging results from a clinical trial, researchers said.
The study, which is expected to be published in a peer-reviewed medical journal soon, found that the new technique, microarray, surpassed standard testing in detecting chromosomal abnormalities that can cause problems like autism or mental retardation.
“The last 8 to 12 months have probably seen the greatest change we’ve had in prenatal screening and diagnostics since the development of amniocentesis,” which became popular in the 1970s, said Dr. Lee Shulman, head of reproductive genetics at Northwestern University’s Feinberg School of Medicine.
The new technique still requires fetal cells to be obtained either by amniocentesis, in which a long needle is stuck into the womb, or by another invasive procedure called chorionic villus sampling, in which tissue is taken from the placenta. But instead of then examining the fetal chromosomes under a microscope, a DNA-sensing chip is used to detect abnormalities too small to be seen...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...